Use of Wharton's jelly-derived mesenchymal stromal cells for the treatment of equine recurrent uveitis: a pilot study

Use of Wharton's jelly-derived mesenchymal stromal cells for the treatment of equine recurrent uveitis: a pilot study

Show other versions (1)

Equine recurrent uveitis (ERU) is a disease that affects 2 to 25 % of equines worldwide, 56% of which go blind; therefore, it is considered the most common cause of blindness in horses. ERU is a spontaneous immune-mediated condition characterized by recurrent intraocular inflammatory events. Currently, there is no treatment for horses with this disease. Mesenchymal stromal cells (MSCs) derived from various tissues, such as Wharton's jelly (WJ), have demonstrated their ability to modulate the immune response by negatively regulating the inflammatory process. The objective of this pilot study was to evaluate the effect of using MSCs derived from WJ as a treatment for ERU. The WJ was obtained and processed according to previously described methodologies for obtaining EMF. The horses involved in this study received a dose of 5x106 MSCs in the subpalpebral area. The research evaluated the concentration of interleukins (IL: IL-1a, IL-2, IL-10, IFN-g, and TNFa) in tear samples obtained before treatment inoculation, 30 min after the inoculation, and 7 days post inoculation. No significant changes in IL concentration were observed suggesting a decrease in pro-inflammatory ILs. However, horses with ERU treated with MSCs exhibited a positive response to therapy, evidenced by a decrease in signs of ERU. The results obtained suggest that treatment of ERU with WJ-derived MSCs is a safe alternative with promising results.

Saved in:
Bibliographic Details
Main Authors: Masri-Daba, María, Camacho-Flores, Montserrat Erandi, Gómez-Romero, Ninnet, Basurto Alcántara, Francisco Javier
Format: Digital revista
Language:spa
eng
Published: Instituto Nacional de Investigaciones Forestales, Agrícolas y Pecuarias 2022
Online Access:https://cienciaspecuarias.inifap.gob.mx/index.php/Pecuarias/article/view/6273
Tags: Add Tag
No Tags, Be the first to tag this record!
id rev-remexcp-article6273
record_format ojs
institution INIFAP
collection OJS
country México
countrycode MX
component Revista
access En linea
databasecode rev-remexcp
tag revista
region America del Norte
libraryname Biblioteca INIFAP
language spa
eng
format Digital
author Masri-Daba, María
Camacho-Flores, Montserrat Erandi
Gómez-Romero, Ninnet
Basurto Alcántara, Francisco Javier
spellingShingle Masri-Daba, María
Camacho-Flores, Montserrat Erandi
Gómez-Romero, Ninnet
Basurto Alcántara, Francisco Javier
Use of Wharton's jelly-derived mesenchymal stromal cells for the treatment of equine recurrent uveitis: a pilot study
author_facet Masri-Daba, María
Camacho-Flores, Montserrat Erandi
Gómez-Romero, Ninnet
Basurto Alcántara, Francisco Javier
author_sort Masri-Daba, María
title Use of Wharton's jelly-derived mesenchymal stromal cells for the treatment of equine recurrent uveitis: a pilot study
title_short Use of Wharton's jelly-derived mesenchymal stromal cells for the treatment of equine recurrent uveitis: a pilot study
title_full Use of Wharton's jelly-derived mesenchymal stromal cells for the treatment of equine recurrent uveitis: a pilot study
title_fullStr Use of Wharton's jelly-derived mesenchymal stromal cells for the treatment of equine recurrent uveitis: a pilot study
title_full_unstemmed Use of Wharton's jelly-derived mesenchymal stromal cells for the treatment of equine recurrent uveitis: a pilot study
title_sort use of wharton's jelly-derived mesenchymal stromal cells for the treatment of equine recurrent uveitis: a pilot study
description Equine recurrent uveitis (ERU) is a disease that affects 2 to 25 % of equines worldwide, 56% of which go blind; therefore, it is considered the most common cause of blindness in horses. ERU is a spontaneous immune-mediated condition characterized by recurrent intraocular inflammatory events. Currently, there is no treatment for horses with this disease. Mesenchymal stromal cells (MSCs) derived from various tissues, such as Wharton's jelly (WJ), have demonstrated their ability to modulate the immune response by negatively regulating the inflammatory process. The objective of this pilot study was to evaluate the effect of using MSCs derived from WJ as a treatment for ERU. The WJ was obtained and processed according to previously described methodologies for obtaining EMF. The horses involved in this study received a dose of 5x106 MSCs in the subpalpebral area. The research evaluated the concentration of interleukins (IL: IL-1a, IL-2, IL-10, IFN-g, and TNFa) in tear samples obtained before treatment inoculation, 30 min after the inoculation, and 7 days post inoculation. No significant changes in IL concentration were observed suggesting a decrease in pro-inflammatory ILs. However, horses with ERU treated with MSCs exhibited a positive response to therapy, evidenced by a decrease in signs of ERU. The results obtained suggest that treatment of ERU with WJ-derived MSCs is a safe alternative with promising results.
publisher Instituto Nacional de Investigaciones Forestales, Agrícolas y Pecuarias
publishDate 2022
url https://cienciaspecuarias.inifap.gob.mx/index.php/Pecuarias/article/view/6273
work_keys_str_mv AT masridabamaria useofwhartonsjellyderivedmesenchymalstromalcellsforthetreatmentofequinerecurrentuveitisapilotstudy
AT camachofloresmontserraterandi useofwhartonsjellyderivedmesenchymalstromalcellsforthetreatmentofequinerecurrentuveitisapilotstudy
AT gomezromeroninnet useofwhartonsjellyderivedmesenchymalstromalcellsforthetreatmentofequinerecurrentuveitisapilotstudy
AT basurtoalcantarafranciscojavier useofwhartonsjellyderivedmesenchymalstromalcellsforthetreatmentofequinerecurrentuveitisapilotstudy
AT masridabamaria usodecelulasestromalesmesenquimalesderivadasdelagelatinadewhartonparaeltratamientodeuveitisrecurrenteequinaestudiopiloto
AT camachofloresmontserraterandi usodecelulasestromalesmesenquimalesderivadasdelagelatinadewhartonparaeltratamientodeuveitisrecurrenteequinaestudiopiloto
AT gomezromeroninnet usodecelulasestromalesmesenquimalesderivadasdelagelatinadewhartonparaeltratamientodeuveitisrecurrenteequinaestudiopiloto
AT basurtoalcantarafranciscojavier usodecelulasestromalesmesenquimalesderivadasdelagelatinadewhartonparaeltratamientodeuveitisrecurrenteequinaestudiopiloto
_version_ 1758023309506641921
spelling rev-remexcp-article62732022-12-27T19:08:50Z Use of Wharton's jelly-derived mesenchymal stromal cells for the treatment of equine recurrent uveitis: a pilot study Uso de células estromales mesenquimales derivadas de la gelatina de Wharton para el tratamiento de uveítis recurrente equina: estudio piloto Masri-Daba, María Camacho-Flores, Montserrat Erandi Gómez-Romero, Ninnet Basurto Alcántara, Francisco Javier Wharton's Jelly; Mesenchymal Stromal Cells; Equine recurrent uveitis; Therapeutics Gelatina de Wharton; Células estromales mesenquimales; Uveítis recurrente equina; Terapéutica Equine recurrent uveitis (ERU) is a disease that affects 2 to 25 % of equines worldwide, 56% of which go blind; therefore, it is considered the most common cause of blindness in horses. ERU is a spontaneous immune-mediated condition characterized by recurrent intraocular inflammatory events. Currently, there is no treatment for horses with this disease. Mesenchymal stromal cells (MSCs) derived from various tissues, such as Wharton's jelly (WJ), have demonstrated their ability to modulate the immune response by negatively regulating the inflammatory process. The objective of this pilot study was to evaluate the effect of using MSCs derived from WJ as a treatment for ERU. The WJ was obtained and processed according to previously described methodologies for obtaining EMF. The horses involved in this study received a dose of 5x106 MSCs in the subpalpebral area. The research evaluated the concentration of interleukins (IL: IL-1a, IL-2, IL-10, IFN-g, and TNFa) in tear samples obtained before treatment inoculation, 30 min after the inoculation, and 7 days post inoculation. No significant changes in IL concentration were observed suggesting a decrease in pro-inflammatory ILs. However, horses with ERU treated with MSCs exhibited a positive response to therapy, evidenced by a decrease in signs of ERU. The results obtained suggest that treatment of ERU with WJ-derived MSCs is a safe alternative with promising results. La uveítis recurrente equina (URE) es una enfermedad que afecta del 2 al 25 % de los equinos a nivel mundial, de los cuales el 56 % se quedan ciegos; por lo tanto, es considerada la causa más común de ceguera en caballos. La URE es un padecimiento espontáneo inmunomediado caracterizado por eventos recurrentes de inflamación intraocular. Actualmente, no existe tratamiento para los caballos con esta enfermedad. Las células estromales mesenquimales (CEM) derivadas de diversos tejidos, como la gelatina de Wharton (GW), han demostrado su capacidad de modular la respuesta inmune al regular negativamente el proceso inflamatorio. El objetivo del presente estudio piloto fue el evaluar el efecto del uso de CEM derivadas de GW como tratamiento para la URE. La GW se obtuvo y procesó con base en metodologías previamente descritas para la obtención de CEM. Los caballos involucrados en este estudio recibieron una dosis de 5x106 CEM en la zona subpalpebral. Se evaluó la concentración de interleucinas (IL) (IL-1a, IL-2, IL-10, IFN-g y TNFa) en muestras de lágrima obtenidas antes de la inoculación del tratamiento, 30 min después y 7 días post inoculación. No se observaron cambios significativos en la concentración de IL que sugieran la disminución de IL proinflamatorias. Sin embargo, los caballos con URE tratados con CEM mostraron una respuesta positiva a la terapia, evidenciada por la disminución en la signología de la URE. Los resultados obtenidos sugieren que el tratamiento de la URE con CEM derivadas de GW es una alternativa segura con resultados prometedores. Instituto Nacional de Investigaciones Forestales, Agrícolas y Pecuarias FMVZ-UNAM INR 2022-12-27 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf application/pdf text/html https://cienciaspecuarias.inifap.gob.mx/index.php/Pecuarias/article/view/6273 10.22319/rmcp.v14i1.6273 Revista Mexicana de Ciencias Pecuarias; Vol. 14, Núm. 1 (2023): Enero-Marzo; 137-153 Revista Mexicana de Ciencias Pecuarias; Vol. 14, Núm. 1 (2023): Enero-Marzo; 137-153 2448-6698 2007-1124 spa eng https://cienciaspecuarias.inifap.gob.mx/index.php/Pecuarias/article/view/6273/5006 https://cienciaspecuarias.inifap.gob.mx/index.php/Pecuarias/article/view/6273/5007 https://cienciaspecuarias.inifap.gob.mx/index.php/Pecuarias/article/view/6273/5045 https://creativecommons.org/licenses/by-nc-sa/4.0

Similar Items